+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), by Study Design, by Indication (Pain Management, Oncology, CNS Condition, Diabetes, Obesity), by Region, and Segment Forecasts, 2022-2030

  • ID: 4396385
  • Report
  • April 2022
  • Region: Global
  • 120 Pages
  • Grand View Research

FEATURED COMPANIES

  • Charles River Laboratory
  • Clinipace
  • Eli Lilly and Company
  • Icon plc
  • Iqvia
  • Novo Nordisk A/S
The global clinical trials market size is expected to reach USD 78.3 billion by 2030, registering a CAGR of 5.8% during the forecast period. An increase in the volume and complexity of clinical trials has been witnessed lately, which plays an important role in the R&D of new drugs and products. The market witnessed a decline of 6% in 2020 owing to the COVID-19 pandemic. However, the market is projected to recover from 2021 onwards. In addition, clinical trials have become increasingly costly, adding to the overall cost of developing a drug.



The increasing need for developing new drugs for chronic diseases, such as cancer, respiratory disorders, diabetes, cardiovascular diseases, and others, is creating immense pressure on the healthcare industry. The COVID-19 pandemic and the increasing demand for developing a suitable treatment are driving the market. The high number of people affected by the disease further depicts an increasing need for therapeutics & vaccines. Currently, there are 288 therapeutics and 106 vaccines under development, out of which, nearly 7.0% of therapeutics are in Phase IV, 21.0% in Phase III, and 43.0% & 13.0% in Phase II & Phase I, respectively.

The pandemic has resulted in the global disruption of traditional onsite clinical trials. Hence, regulatory bodies worldwide have undertaken various initiatives for fast-tracking clinical trials for the development of innovative solutions. One such instance is Solidarity, an international clinical trial launched by the WHO to find effective treatment against COVID-19. Although the pandemic has forced many medical device & drug developers to revise the approach to such crises, integrating best practices within clinical trial procedures & adapting to virtual trials, which can support the continuous development of therapeutics.

Clinical Trials Market Report Highlights

  • The phase III clinical trials segment dominated the market with a 53.4% share in 2021. This can be attributed to the complexity of this phase.
  • The interventional design segment accounted for the largest share of 45.7% in 2021 in the study design segment owing to the increasing demand for the intervention for clinical trials by researchers.
  • North America held 50.7% of the market share in 2021. Favorable government initiatives and the presence of a large number of players in the U.S. that offer advanced services are responsible for market growth.
  • The Asia Pacific region is expected to grow at the fastest CAGR of 6.8% over the forecast period owing to the increasing patient pool and cost-efficient services.
Frequently Asked Questions about the Global Clinical Trials Market

What is the estimated value of the Global Clinical Trials Market?

The Global Clinical Trials Market was estimated to be valued at $49.8 Billion in 2022.

What is the growth rate of the Global Clinical Trials Market?

The growth rate of the Global Clinical Trials Market is 5.8%, with an estimated value of $78.3 Billion by 2030.

What is the forecasted size of the Global Clinical Trials Market?

The Global Clinical Trials Market is estimated to be worth $78.3 Billion by 2030.

Who are the key companies in the Global Clinical Trials Market?

Key companies in the Global Clinical Trials Market include Iqvia, Parexel International Corporation, Pharmaceutical Product Development, LLC, Charles River Laboratory, Icon plc, Wuxi Apptec Inc, Pra Health Sciences, Sgs Sa and Chiltern International Ltd.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Charles River Laboratory
  • Clinipace
  • Eli Lilly and Company
  • Icon plc
  • Iqvia
  • Novo Nordisk A/S

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Phase
1.1.2. Study Design
1.1.3. Indication
1.1.4. Regional Scope
1.1.5. Estimates and Forecast Timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. Internal Database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.4. Information or Data Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity Flow Analysis (Model 1)
1.6.1.1. Approach 1: Commodity Flow Approach
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1: Understanding the Market Dynamics
1.9.2. Objective 2: Understanding the Market Estimates and Forecasts
1.9.3. Objective 3: Understanding the Attributes such as Strategy Framework, Competitor Categorization
1.9.4. Objective 4: Understanding the Key Product and Application Scopes to Conclude on the Market Size
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Clinical Trials Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Product Pipeline Analysis, by Stage
3.3.1. Therapeutics in Development
3.3.2. Vaccines in Development
3.4. Fast-Track of Clinical Trials
3.4.1. FDA Initiative-CTPA
3.4.2. U.K. Initiative-ACCORD
3.4.3. ASIA Pacific Initiative-DCGI
3.4.4. University of Pittsburgh School of Medicine-UPMC
3.5. Solidarity Clinical Trials
3.5.1. Participation in Solidarity Trials
3.5.2. Solidarity Clinical Trial for Vaccines
3.6. Virtual Clinical Trials
3.6.1. In-Home Clinical Services
3.7. COVID-19 Impact on Clinical Trials
3.7.1. Companies with Phase 1 Trial Disruption
3.7.2. Companies with Phase 2 Trial Disruption
3.7.3. Companies with Phase 3 Trial Disruption
3.8. Market Dynamics
3.8.1. Market Driver Analysis
3.8.1.1. Increasing Research and Development Promoting Outsourcing
3.8.1.2. Adoption of New Technology in Clinical Research
3.8.1.3. Increasing Prevalence of Chronic Disease
3.8.1.4. Globalization of Clinical Trials
3.8.2. Market Restraint Analysis
3.8.2.1. Stringent Regulatory Policies for Patient Enrollment
3.8.2.2. Lack of Skilled Workforce in Clinical Research
3.8.3. Industry Challenges
3.8.3.1. Rising Cost of Clinical Trial
3.9. Clinical Trials: Market Analysis Tools
3.9.1. Industry Analysis-Porter’s
3.9.1.1. Supplier Power
3.9.1.2. Buyer Power
3.9.1.3. Substitution Threat
3.9.1.4. Threat from New Entrant
3.9.1.5. Competitive Rivalry
3.9.2. PESTEL Analysis
3.9.2.1. Political Landscape
3.9.2.2. Environmental Landscape
3.9.2.3. Social Landscape
3.9.2.4. Technology Landscape
3.9.2.5. Legal Landscape
3.9.3. Major Deals & Strategic Alliances Analysis
Chapter 4. Clinical Trials Market: Segment Analysis, by Phase, 2017-2030 (USD Million)
4.1. Definitions & Scope
4.2. Phase Market Share Analysis, 2021 & 2030
4.3. Segment Dashboard
4.4. Global Clinical Trials Market, by Phase, 2017 to 2030
4.5. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the Following
4.5.1. Phase I
4.5.2. Phase II
4.5.3. Phase III
4.5.4. Phase IV
Chapter 5. Clinical Trials Market: Segment Analysis, by Study Design, 2017-2030 (USD Million)
5.1. Definitions & Scope
5.2. Study Design Market Share Analysis, 2021 & 2030
5.3. Segment Dashboard
5.4. Global Clinical Trials Market, by Study Design, 2017 to 2030
5.5. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
5.5.1. Interventional
5.5.2. Observational
5.5.3. Expanded Access
Chapter 6. Clinical Trials Market: Segment Analysis, by Indication, 2017-2030 (USD Million)
6.1. Definitions & Scope
6.2. Indication Market Share Analysis, 2021 & 2030
6.3. Segment Dashboard
6.4. Global Clinical Trials Market, by Indication, 2017 to 2030
6.5. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
6.5.1. Autoimmune/Inflammation
6.5.2. Pain Management
6.5.3. Oncology
6.5.4. CNS Condition
6.5.5. Diabetes
6.5.6. Obesity
6.5.7. Cardiovascular
6.5.8. Others
Chapter 7. Clinical Trials Market: Segment Analysis, Indication by Study Design, 2017-2030 (USD Million)
7.1. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
7.1.1. Autoimmune/inflammation
7.1.1.1. Interventional
7.1.1.2. Observational
7.1.1.3. Expanded Access
7.1.2. Pain Management
7.1.2.1. Interventional
7.1.2.2. Observational
7.1.2.3. Expanded Access
7.1.3. Oncology
7.1.3.1. Interventional
7.1.3.2. Observational
7.1.3.3. Expanded Access
7.1.4. CNS condition
7.1.4.1. Interventional
7.1.4.2. Observational
7.1.4.3. Expanded Access
7.1.5. Diabetes
7.1.5.1. Interventional
7.1.5.2. Observational
7.1.5.3. Expanded Access
7.1.6. Obesity
7.1.6.1. Interventional
7.1.6.2. Observational
7.1.6.3. Expanded Access
7.1.7. Cardiovascular
7.1.7.1. Interventional
7.1.7.2. Observational
7.1.7.3. Expanded Access
7.1.8. Others
7.1.8.1. Interventional
7.1.8.2. Observational
7.1.8.3. Expanded Access
Chapter 8. Clinical Trials Market: Segment Analysis, by Sponsor, 2017-2030 (USD Million)
8.1. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the Following
8.1.1. Pharmaceutical & Biopharmaceutical Companies
8.1.2. Medical Device Companies
8.1.3. Others
Chapter 9. Clinical Trials Market: Regional Market Analysis, by Region, 2017-2030 (USD Million)
9.1. Definitions & Scope
9.2. Regional Market Share Analysis, 2021 & 2030
9.3. Regional Market Dashboard
9.4. Regional Market Share, 2020
9.5. Market Size, & Forecasts, and Trend Analysis, 2017 to 2030:
9.6. North America
9.6.1. Market Estimates and Forecast, by Country, 2017-2030 (USD Million)
9.6.2. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.6.3. Market Estimates and Forecast, by Study design, 2017-2030 (USD Million)
9.6.4. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.6.5. U.S.
9.6.5.1. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.6.5.2. Market Estimates and Forecast, by Study Design, 2017-2030 (USD Million)
9.6.5.3. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.6.5.4. Market Estimates and Forecast, by Sponsor, 2017-2030 (USD Million)
9.6.6. Canada
9.6.6.1. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.6.6.2. Market Estimates and Forecast, by study design, 2017-2030 (USD Million)
9.6.6.3. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.6.6.4. Market Estimates and Forecast, by Sponsor, 2017-2030 (USD Million)
9.7. Europe
9.7.1. Market Estimates and Forecast, by country, 2017-2030 (USD Million)
9.7.2. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.7.3. Market Estimates and Forecast, by study design, 2017-2030 (USD Million)
9.7.4. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.7.5. Market Estimates and Forecast, by Sponsor, 2017-2030 (USD Million)
9.7.6. Germany
9.7.6.1. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.7.6.2. Market Estimates and Forecast, by study design, 2017-2030 (USD Million)
9.7.6.3. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.7.6.4. Market Estimates and Forecast, by Sponsor, 2017-2030 (USD Million)
9.7.7. U.K.
9.7.7.1. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.7.7.2. Market Estimates and Forecast, by Study Design, 2017-2030 (USD Million)
9.7.7.3. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.7.7.4. Market Estimates and Forecast, by Sponsor, 2017-2030 (USD Million)
9.7.8. France
9.7.8.1. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.7.8.2. Market Estimates and Forecast, by Study Design, 2017-2030 (USD Million)
9.7.8.3. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.7.8.4. Market Estimates and Forecast, by Sponsor, 2017-2030 (USD Million)
9.7.9. Italy
9.7.9.1. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.7.9.2. Market Estimates and Forecast, by Study Design, 2017-2030 (USD Million)
9.7.9.3. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.7.9.4. Market Estimates and Forecast, by Sponsor, 2017-2030 (USD Million)
9.7.10. Spain
9.7.10.1. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.7.10.2. Market Estimates and Forecast, by Study Design, 2017-2030 (USD Million)
9.7.10.3. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.7.10.4. Market Estimates and Forecast, by Sponsor, 2017-2030 (USD Million)
9.8. Asia Pacific
9.8.1. Market Estimates and Forecast, by country, 2017-2030 (USD Million)
9.8.2. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.8.3. Market Estimates and Forecast, by Study Design, 2017-2030 (USD Million)
9.8.4. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.8.5. Market Estimates and Forecast, by Sponsor, 2017-2030 (USD Million)
9.8.6. China
9.8.6.1. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.8.6.2. Market Estimates and Forecast, by Study Design, 2017-2030 (USD Million)
9.8.6.3. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.8.6.4. Market Estimates and Forecast, by Sponsor, 2017-2030 (USD Million)
9.8.7. Japan
9.8.7.1. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.8.7.2. Market Estimates and Forecast, by Study Design, 2017-2030 (USD Million)
9.8.7.3. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.8.7.4. Market Estimates and Forecast, by Sponsor, 2017-2030 (USD Million)
9.8.8. India
9.8.8.1. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.8.8.2. Market Estimates and Forecast, by Study Design, 2017-2030 (USD Million)
9.8.8.3. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.8.8.4. Market Estimates and Forecast, by Sponsor, 2017-2030 (USD Million)
9.8.9. Australia
9.8.9.1. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.8.9.2. Market Estimates and Forecast, by Study Design, 2017-2030 (USD Million)
9.8.9.3. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.8.9.4. Market Estimates and Forecast, by Sponsor, 2017-2030 (USD Million)
9.8.10. South Korea
9.8.10.1. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.8.10.2. Market Estimates and Forecast, by Study Design, 2017-2030 (USD Million)
9.8.10.3. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.8.10.4. Market Estimates and Forecast, by Sponsor, 2017-2030 (USD Million)
9.9. Latin America
9.9.1. Market Estimates and Forecast, by country, 2017-2030 (USD Million)
9.9.2. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.9.3. Market Estimates and Forecast, by Study Design, 2017-2030 (USD Million)
9.9.4. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.9.5. Market Estimates and Forecast, by Sponsor, 2017-2030 (USD Million)
9.9.6. Brazil
9.9.6.1. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.9.6.2. Market Estimates and Forecast, by Study Design, 2017-2030 (USD Million)
9.9.6.3. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.9.6.4. Market Estimates and Forecast, by Sponsor, 2017-2030 (USD Million)
9.9.7. Mexico
9.9.7.1. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.9.7.2. Market Estimates and Forecast, by Study Design, 2017-2030 (USD Million)
9.9.7.3. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.9.7.4. Market Estimates and Forecast, by Sponsor, 2017-2030 (USD Million)
9.9.8. Argentina
9.9.8.1. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.9.8.2. Market Estimates and Forecast, by Study Design, 2017-2030 (USD Million)
9.9.8.3. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.9.8.4. Market Estimates and Forecast, by Sponsor, 2017-2030 (USD Million)
9.9.9. Colombia
9.9.9.1. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.9.9.2. Market Estimates and Forecast, by Study Design, 2017-2030 (USD Million)
9.9.9.3. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.9.9.4. Market Estimates and Forecast, by Sponsor, 2017-2030 (USD Million)
9.10. Middle East and Africa
9.10.1. Market Estimates and Forecast, by country, 2017-2030 (USD Million)
9.10.2. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.10.3. Market Estimates and Forecast, by Study Design, 2017-2030 (USD Million)
9.10.4. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.10.5. Market Estimates and Forecast, by Sponsor, 2017-2030 (USD Million)
9.10.6. South Africa
9.10.6.1. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.10.6.2. Market Estimates and Forecast, by Study Design, 2017-2030 (USD Million)
9.10.6.3. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.10.6.4. Market Estimates and Forecast, by Sponsor, 2017-2030 (USD Million)
9.10.7. Saudi Arabia
9.10.7.1. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.10.7.2. Market Estimates and Forecast, by Study Design, 2017-2030 (USD Million)
9.10.7.3. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.10.7.4. Market Estimates and Forecast, by Sponsor, 2017-2030 (USD Million)
9.10.8. UAE
9.10.8.1. Market Estimates and Forecast, by Phase, 2017-2030 (USD Million)
9.10.8.2. Market Estimates and Forecast, by Study Design, 2017-2030 (USD Million)
9.10.8.3. Market Estimates and Forecast, by Indication, 2017-2030 (USD Million)
9.10.8.4. Market Estimates and Forecast, by Sponsor, 2017-2030 (USD Million)
Chapter 10. Clinical Trials Market-Competitive Analysis
10.1. Key Companies Profiled
10.1.1. IQVIA
10.1.1.1. Company Overview
10.1.1.2. Financial Performance
10.1.1.3. Product Benchmarking
10.1.1.4. Strategic Initiatives
10.1.2. PAREXEL International Corporation
10.1.2.1. Company Overview
10.1.2.2. Financial Performance
10.1.2.3. Product Benchmarking
10.1.2.4. Strategic Initiatives
10.1.3. Pharmaceutical Product Development, LLC
10.1.3.1. Company Overview
10.1.3.2. Financial Performance
10.1.3.3. Product Benchmarking
10.1.3.4. Strategic Initiatives
10.1.4. Charles River Laboratory
10.1.4.1. Company Overview
10.1.4.2. Financial Performance
10.1.4.3. Product Benchmarking
10.1.4.4. Strategic Initiatives
10.1.5. ICON Plc
10.1.5.1. Company Overview
10.1.5.2. Financial Performance
10.1.5.3. Product Benchmarking
10.1.5.4. Strategic Initiatives
10.1.6. Wuxi AppTec Inc
10.1.6.1. Company Overview
10.1.6.2. Financial Performance
10.1.6.3. Product Benchmarking
10.1.6.4. Strategic Initiatives
10.1.7. PRA Health Sciences
10.1.7.1. Company Overview
10.1.7.2. Financial Performance
10.1.7.3. Product Benchmarking
10.1.7.4. Strategic Initiatives
10.1.8. SGS SA
10.1.8.1. Company Overview
10.1.8.2. Financial Performance
10.1.8.3. Product Benchmarking
10.1.8.4. Strategic Initiatives
10.1.9. Syneos Health
10.1.9.1. Company Overview
10.1.9.2. Financial Performance
10.1.9.3. Product Benchmarking
10.1.9.4. Strategic Initiatives
10.1.10. Chiltern International Ltd
10.1.10.1. Company Overview
10.1.10.2. Financial Performance
10.1.10.3. Product Benchmarking
10.1.10.4. Strategic Initiatives
10.1.11. Eli Lilly and Company
10.1.11.1. Company Overview
10.1.11.2. Financial Performance
10.1.11.3. Product Benchmarking
10.1.11.4. Strategic Initiatives
10.1.12. Novo Nordisk A/S
10.1.12.1. Company Overview
10.1.12.2. Financial Performance
10.1.12.3. Product Benchmarking
10.1.12.4. Strategic Initiatives
10.1.13. Pfizer
10.1.13.1. Company Overview
10.1.13.2. Financial Performance
10.1.13.3. Product Benchmarking
10.1.13.4. Strategic Initiatives
10.1.14. Clinipace
10.1.14.1. Company Overview
10.1.14.2. Financial Performance
10.1.14.3. Product Benchmarking
10.1.14.4. Strategic Initiatives
Note: Product cover images may vary from those shown
  • IQVIA
  • PAREXEL International Corporation
  • Pharmaceutical Product Development, LLC
  • Charles River Laboratory
  • ICON Plc
  • Wuxi AppTec Inc
  • PRA Health Sciences
  • SGS SA
  • Syneos Health
  • Chiltern International Ltd
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Pfizer
  • Clinipace
Note: Product cover images may vary from those shown

Loading
LOADING...